Valeant Pharmaceuticals North America LLC, commonly referred to as Valeant, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1960, the company has established a strong presence across North America, focusing on specialty pharmaceuticals and over-the-counter products. Valeant is renowned for its diverse portfolio, which includes dermatology, ophthalmology, and neurology products, setting it apart through innovative formulations and targeted therapies. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position and expanded its product offerings. With a commitment to addressing unmet medical needs, Valeant continues to make strides in the healthcare sector, solidifying its reputation as a leader in the pharmaceutical landscape.
How does Valeant Pharmaceuticals North America LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Valeant Pharmaceuticals North America LLC's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Valeant Pharmaceuticals North America LLC, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the pharmaceutical industry is increasingly focusing on sustainability and reducing greenhouse gas emissions. Companies are encouraged to adopt science-based targets and engage in initiatives that promote environmental responsibility. Valeant's commitment to climate action may align with industry trends, but specific details on their initiatives or targets are not provided.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Valeant Pharmaceuticals North America LLC is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.